Thanks for your feedback.
All I see is combo studies. Nktr needs to work with the combo drug maker and split the cost of the trials.
HR does not have the mental capacity to manage this drug development program.
Interesting. If you follow Obamacare, 2017 cost increase is expected up to 30%. Well that will not happen. Something has to give. Congress/Obama did not think this out.
Everyone has to have a policy. The policy services offered will be cut to balance revenue in and expenses out.
Does the government want to start a Multi billion drug when a off the shelve drug is the responsibility of the patient to pay the cost. I am covered by a great plan. Others who are part time are covered by medicare/state for free.
there are self employed workers who are not so lucky These people actually pay up to 20K of real real money.
I think everything will change on what drugs are offered. So I can see a drug costing 5000% more. Getting new drugs approved is costing so much more.
Doctors are striking and that is not suppose to happen......
AstraZeneca & Daiichi Sankyo co-promoting in U.S.
with 1,000+ reps in primary care and specialty care
• Average weekly Total Rx in February ~6,500 with
more than 40% of Rx coming from continuing patients*
with very positive physician and patient reception
Direct-to-consumer (DTC) awareness campaigns
expanding to reach high number of OIC patients
As of January 2016, Tier 2 reimbursement now in
place with primary placement for treatment of OIC
Royalty rate in U.S. starts at 20%
Marketed in EU as Moventig by ProStrakan
• Nektar’s 2016 portion of EU milestones estimated to be
over $40 million with royalties of high single digits to
low double digits
Nektar also entitled to global sales milestones
Based on what we know about NKTR 214 215 102. Could form a standalone company. 10B today but with stronger NKTR Phase 1/2 data. The Combo drug company may start a bidding war. It would take a 10%CR company to a 40-60%CR
44% the FDA usually approved drugs based on the objective overall response rate (ORR),
Don't confuse 44% ORR with 40-60% CRs. NKTR 214 may be a 100% ORR. and for much longer.
I would like to know about Movantik milestone payment. 384M When to expect it. 2016 or 2017. With Movantik sales surging, we have to have a solid target date. It may be that NKTR 214 Phase 3 and 384M all come together at the same time.
Positioned To Grow And Lead EHL
• ADYNOVATE launched in U.S. during Q4 2015
- Single-digit price premium to ADVATE on an annual
cost of therapy basis
- 60%+ HTC penetration with positive patient/prescriber
response to product profile
• Strong IP Position
- First approval of EHL product utilizing proprietary PEG
- Exclusive licenses to NektarTherapeutics FVIII patents
and patent applications
• U.S. pediatric and EU filing completed Q1 2016
• Japan approval received Q1 2016; mid-year
launch aligned with reimbursement approval • Initiated PUP study Q4 2015
By business, global hematology revenues of $843 million increased 8 percent (excluding the impact of foreign currency) as the company continues to focus on enhancing access and
elevating standards of care worldwide. Growth was driven by the U.S. introduction of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life
recombinant Factor VIII (rFVIII) treatment for hemophilia A, as well as heightened demand for ADVATE [Antihemophilic Factor (Recombinant)] and FEIBA [Anti-Inhibitor Coagulant
Complex], an inhibitor treatment. Also contributing to performance was growth of RIXUBIS [Coagulation Factor IX (Recombinant)], a treatment for hemophilia B, and OBIZUR
[Antihemophilic Factor (Recombinant), Porcine Sequence], for the treatment of acquired hemophilia A.
Effect of cancer vaccine formulation on synergy with anti-CTLA-4 and anti-PD-L1 checkpoint blockade therapy of cancer.
Poster Board: #416
Yared Hailemichael, PhD - Presenter
The University of Texas MD Anderson Cancer Center
Immune memory in nonclinical models after treatment with NKTR-214, an engineered cytokine biased towards expansion of CD8+ T cells in tumor.
Poster Board: #242
Deborah H. Charych, Ph.D. - Presenter
BXLT has approx 6B in revenue. Existing products like Advate, Feiba and HyQvia and newly launched product Adynovate should continue to contribute to top-line growth.
Companies do not usually discuss small drugs. BXLT should cover the top 5-10 drug in their portfolio. As DCX said, some ramp.....